Yusri Elsayed, SVP & Global Oncology Therapeutic Area Head at Johnson & Johnson Innovative Medicine, shared a post on LinkedIn:
“As we close out the 2026 American Society of Clinical Oncology (ASCO), Annual Meeting, I want to take a moment to express my deepest gratitude and appreciation to our Johnson & Johnson teams and collaborators who poured their hearts and ingenuity into advancing treatments for patients living with cancer.
The innovations showcased at this year’s ASCO were nothing short of extraordinary — from the plenary opener featuring ERLEADA’s PROTEUS study in high-risk localized prostate cancer, to impressive Rybrevant data in recurrent and metastatic head and neck squamous cell carcinoma, to the compelling results with Tecvayli in relapsed and refractory multiple myeloma – along with several other impactful presentations.
Together, these milestones are a testament to our unwavering commitment to improve and extend the lives of cancer patients — and to continue our march toward a future where cancer is eliminated.
Thank you to everyone who made this possible.”
Other articles featuring Yusri Elsayed on OncoDaily.